이상반응 보고
| VAERS ID | 2247491 |
|---|---|
| 성별 | 남성 |
| 나이 | 72세 |
| 주 코드 | FR |
| 제약회사 | MODERNA |
| 로트 번호 | |
| 예방접종 횟수 | 3 |
| 접종일 | 2022-03-17 |
| 발병일 | 2022-03-18 |
| 상태 | 입원 |
증상
- 발열(Pyrexia)
- 식욕 감소(Decreased appetite)
- 근육통(Myalgia)
이환 중 질병
지병
기타 의료
이전 예방접종
알레르기
임상 검사
증상 상세
Fever; Body soreness and poor appetite; Body soreness and poor appetite; This regulatory authority case was reported by an other health care professional and describes the occurrence of PYREXIA (Fever), MYALGIA (Body soreness and poor appetite) and DECREASED APPETITE (Body soreness and poor appetite) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.
No Medical History information was reported.
On 17-Mar-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.
On 18-Mar-2022, the patient experienced PYREXIA (Fever) (seriousness criterion hospitalization), MYALGIA (Body soreness and poor appetite) (seriousness criterion hospitalization) and DECREASED APPETITE (Body soreness and poor appetite) (seriousness criterion hospitalization).
At the time of the report, PYREXIA (Fever), MYALGIA (Body soreness and poor appetite) and DECREASED APPETITE (Body soreness and poor appetite) was resolving.
For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
The patient went to Clinic to receive Moderna COVID-19 vaccine (the third dose) on 17-Mar-2022.
In the afternoon on 18-Mar-2022, the patient began to feel uncomfortable, aching, fever and poor appetite all over the body, and went to the emergency department of our hospital at 22:24, with BP 143/80 mmHg, PR 112 BPM, RR 19 times per min, BT 38.
5 Degree Celsius and SpO2 95 percentage.
The patient was treated with lyacety 1 vial and Dexamethasone 1 amp STAT, and left the hospital at 22:36.
At 23:44 on March 19, 2022, the patient had intermittent fever for 4 hours; and received intake of antipyretic but with recurrence of fever and went to the emergency department again, with BP 132/83 mmHg, PR 118 BPM, RR 20 times per min, BT 37.
4 Degree Celsius, and SPO2 95 percentage, CBC/Dc showed leucocytosis with leftward shift, no anemia, normal platelet count; CRP equals 6.
44, Urinalysis showed 3(Plus) pyuria, (Plus) nitrites, numerous WBC/HPF, Chest x-ray showed increased bilateral lung infiltrations, and at 06:50 on 20-Mar-2022, BT: 39.
6, and at 08:57, the patient was hospitalized for treatments.
The patient will come to the hospital for consultation, and the body was significantly improved.
Company comment: This regulatory case concerns a 72-year-old, male patient with no reported medical history, who was hospitalized for the unexpected events of Pyrexia, Myalgia and Decreased appetite.
The events occurred a day after receiving the third dose of mRNA-1273 and was seen in the emergency department with elevated blood pressure (BP 143/80 mmHg), tachycardia (112 bpm) and moderate-grade fever (38.
5 degrees Celsius).
There was no note of difficulty of breathing and the oxygen saturation was within normal (95%, respiratory rate 19 times/min).
The patient was given Lysine Acetylsalicylate (Lyacety) and Dexamethasone and was also discharged on the same day.
On the next day, the patient still had fever, intermittent despite anti-pyretics, and returned to the ED with admitting vital signs of elevated BP (132/83 mmHg), tachycardia (118 bpm) but with normal respiration and temperature.
Blood count showed leucocytosis with leftward shift, no anemia and with normal platelet count.
On urinalysis, there was pyuria (3+) and numerous white blood cells.
Chest X-ray revealed bilateral lung infiltrates.
The patient was admitted as in-patient and was given unspecified treatment.
He was discharged on an unspecified date, improved.
The benefit-risk relationship of mRNA-1273 is not affected by this report.
Events' seriousness was assessed as per Regulatory Authority's report.
; Sender's Comments: This regulatory case concerns a 72-year-old, male patient with no reported medical history, who was hospitalized for the unexpected events of Pyrexia, Myalgia and Decreased appetite.
The events occurred a day after receiving the third dose of mRNA-1273 and was seen in the emergency department with elevated blood pressure (BP 143/80 mmHg), tachycardia (112 bpm) and moderate-grade fever (38.
5 degrees Celsius).
There was no note of difficulty of breathing and the oxygen saturation was within normal (95%, respiratory rate 19 times/min).
The patient was given Lysine Acetylsalicylate (Lyacety) and Dexamethasone and was also discharged on the same day.
On the next day, the patient still had fever, intermittent despite anti-pyretics, and returned to the ED with admitting vital signs of elevated BP (132/83 mmHg), tachycardia (118 bpm) but with normal respiration and temperature.
Blood count showed leucocytosis with leftward shift, no anemia and with normal platelet count.
On urinalysis, there was pyuria (3+) and numerous white blood cells.
Chest X-ray revealed bilateral lung infiltrates.
The patient was admitted as in-patient and was given unspecified treatment.
He was discharged on an unspecified date, improved.
The benefit-risk relationship of mRNA-1273 is not affected by this report.
Events' seriousness was assessed as per Regulatory Authority's report.